Induced pluripotent stem (iPS) cells are actively being used in clinical trials as potential therapeutic treatments for neurodegenerative disease, cardiovascular disease, and more. The process of translating iPS cell research into a therapy can be daunting and undefined. In particular, it is critical for researchers to maintain the quality and consistency of the iPS cells or their differentiated derivatives during the translation process, all while minimizing costs.
This webinar will provide technical and tactical considerations that will help researchers improve the efficiency of their workflow as they begin translating their iPS cell research into a therapy.
What will you learn?
- Techniques for iPSC validation
- Ways to minimize iPS cell line variation
- When to incorporate GMP Proteins into your workflow
- What to look for in a GMP manufacturer
Who may this interest?
- Induced pluripotent stem cell researchers
- Stem cell core facilities
- Regenerative medicine companies
- Cell therapy companies
- Principal invesitgators
- Postdoctoral researchers
Fabrizio Rinaldi, PhD
Fabrizio Rinaldi, PhD, is a Research and Development Scientist for Stem Cell Products at R&D Systems, a Bio-Techne brand. Fabrizio received a PhD in Advanced Technologies in Biomedicine from the University of Rome - Tor Vergata and did a Postdoc at the University of Minnesota in the laboratory of Rita Perlingeiro. Fabrizio has extensive experience working with induced pluripotent stem cells, including reprogramming, expansion, and differentiation.
Tim Manning, PhD
Tim Manning is the Product Manager for Proteins at R&D Systems, a Bio-Techne brand. Tim has an extensive knowledge of protein production, quality control, and GMP guidelines. Tim received his PhD in Neuroscience from University of Alabama at Birmingham.
For a full list of other webinars available on RegMedNet please see here.